Skip navigation
MOST POPULAR RELATED TAGS
  • TOPICS
  • SECTORS
  • COMPANIES
Pharmas Market Video Gallery
Abbott Laboratories' Niaspan beat Merck's Zetia in a new study. CNBC's Mike Huckman has the details.
Abbott Laboratories' Niaspan beat Merck's Zetia in a new study. Dr. Steven Nissen, chairman of the Department of Cardiov...
PHARMA WATCH LIST
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...

SPECIAL REPORT


Current DateTime: 05:51:20 16 Nov 2009
LinksList Documentid: 32984624

PHARMA'S MARKET VIDEO

» More

Current DateTime: 05:51:20 16 Nov 2009
LinksList Documentid: 31171988
Expiration DateTime: 11/16/2009 5:54:08 PM

RSS FEED

» Help

Current DateTime: 05:51:21 16 Nov 2009
LinksList Documentid: 31171995
powered by digg

Pharma's Market

Text Size
Jul.24
11:25 AM ET
Thursday, 24 Jul 2008
Lilly, Pfizer & The Economies of ED

So, yesterday I posited a theory that the weak American economy might be hurting sales growth of erectile dysfunction drugs.

The drugs are so pricey and may not be covered by insurance, so I wondered whether men might be cutting their pills in half and/or not filling their expensive prescriptions if they're having to tighten their belts.

I called attention to the fact that U.S. sales of Pfizer's [PFE  Loading...      ()   ] Viagra went down sequentially. Analysts say that happened even with a nine percent Viagra price increase during the quarter. And BMO Capital Markets' Bert Hazlett says in a research note to clients this morning that Viagra prescriptions did indeed drop by four percent in Q2.

Yesterday, GlaxoSmithKline [GSK  Loading...      ()   ] reported sequentially flat sales of Levitra. But revenue from that impotence pill is so small ($26 million), it really doesn't register.

Then, this morning, Eli Lilly [LLY  Loading...      ()   ] announced that second quarter sales of Cialis in the U.S. went up only $5 million from the first quarter. And here, too, the company acknowledges that it raised the price. Deutsche Bank's Barbara Ryan says total worldwide prescriptions of Cialis are up six percent so far this year. So, maybe Cialis--because it lasts a day-and-a-half versus Levitra and Viagra which last a few hours or so--is simply taking more market share. Lilly also recently launched a one-a-day version of Cialis.

In a "First on CNBC" interview on "Squawk Box" this morning new LLY CEO John Lechleiter said, "I don't think we've got a good read on whether the economy is affecting Cialis sales or not." And he mentioned something interesting that I wasn't aware of: "It's the only product overseas that is not price restricted, so it's a product most people pay for out of their pocket."

But my case may be bolstered by a Dr. Benjamin Brewer who writes "The Doctor's Office" column for The Wall Street Journal. Yesterday, in a piece about the economy's impact on healthcare he offered this anecdote: "I'm getting fewer fill (prescription) requests for E.D. drugs, like Viagra, too."

Who knew that erectile dysfunction drug prescriptions might be an economic indicator? I will resist trying to coin a term for that.

Questions?  Comments? 

© 2009 CNBC, Inc. All Rights Reserved

Tools:
PrintEmailAdd This share icon
Next Post
  • digg share
ADD COMMENTS
Remaining characters


Current DateTime: 04:09:30 16 Nov 2009
LinksList Documentid: 29778428

Current DateTime: 04:09:40 16 Nov 2009
LinksList Documentid: 29779196

Current DateTime: 04:01:03 16 Nov 2009
LinksList Documentid: 29779199

Current DateTime: 04:09:29 16 Nov 2009
LinksList Documentid: 29779198
  Data is a real-time snapshot  *Data is delayed at least 15 minutes
Global Business and Financial News, Stock Quotes, and Market Data and Analysis

© 2009 CNBC, Inc.  All Rights Reserved.
A Division of NBC Universal
Thomson ReutersThomson Reuters